EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial

Kristoffer Berg-Hansen, Andreas Bugge Tinggaard, Roni Nielsen, Thomas Hvid Jensen, Nigopan Gopalasingam, Anders Hostrup Larsen, Niels Møller, Morten Böttcher, Malene Hollingdal, Mikael Kjær Poulsen, Lisbeth Antonsen, Toru Kondo und 10 weitere

Journal of Cardiac Failure · 2026-06 · 32 (6) · 1050-1058

DOI: 10.1016/j.cardfail.2025.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2026-06. Verfasst von Kristoffer Berg-Hansen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Anaesthesiology and Intensive Care, Horsens Regional Hospital, H…. Hauptthemen laut MEDLINE: Heart Failure, Butylene Glycols, Hospitalization, Ketone Bodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute heart failure (AHF) is associated with high mortality rates, and contemporary medical treatments provide limited benefits in survival. Emerging evidence suggests that exogenous ketone bodies may have beneficial cardiovascular effects in patients with heart failure. The KETO-AHF (KETOne Supplements in Patients Hospitalized for Acute Heart Failure) trial is designed to assess the clinical benefits of initiating ketone supplementation with 1,3-butanediol compared with placebo in patients hospitalized for AHF with reduced ejection fraction. METHODS: KETO-AHF is a multicenter, randomized, double-blind, placebo-controlled trial investigating the effects of 1,3-butanediol (33 g 3 times daily) in patients hospitalized for AHF. Patients with symptoms and signs of AHF requiring intravenous loop diuretics and/or vasoactive treatment, elevated natriuretic peptides, and a left ventricular ejection fraction ≤ 35%, whether de novo or known heart failure, will be enrolled within 5 days of hospital admission. Participants will be randomized 1:1 to receive either 1,3-butanediol or placebo for a 30-day treatment period. The study aims to enroll 125 patients in each group. The primary endpoint is a hierarchical composite of all-cause mortality, heart failure rehospitalization, 6-minute walk test improvement, and reduction in NT-proBNP levels at 30 days. CONCLUSION: The KETO-AHF trial will provide insights into the effects of supplementation with the ketone body 1,3-butanediol in patients hospitalized for AHF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureButylene GlycolsHospitalizationKetone BodiesDietary SupplementsHumansDouble-Blind MethodAcute DiseaseRandomized Controlled Trials as TopicMulticenter Studies as TopicFemaleMaleTreatment OutcomeStroke Volume

Stichwörter der Autor:innen

1,3-butanediolAcute heart failureketone bodiesmetabolism

Substanzen

Butylene GlycolsKetone Bodies1,3-butylene glycol

Autor:innen und Institutionen

  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Anaesthesiology and Intensive Care, Horsens Regional Hospital, Horsens, Denmark. Electronic address: krisbe@rm.dk.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Cardiology, Gødstrup Hospital, Herning, Denmark.
  • Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Cardiology, Gødstrup Hospital, Herning, Denmark.
  • Department of Cardiology, Viborg Hospital, Viborg, Denmark.

Förderung

  • Novo Nordisk Foundation

Zitieren

APA

Berg-Hansen, K., Tinggaard, A. B., Nielsen, R., Jensen, T. H., Gopalasingam, N., Larsen, A. H., Møller, N., Böttcher, M., Hollingdal, M., Poulsen, M. K., Antonsen, L., Kondo, T., Jhund, P. S., Borlaug, B. A., Mebazaa, A., Møller, J. E., Vraa, S., Grand, J., Hove, J. D., …, & Wiggers, H. (2026). Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial. Journal of Cardiac Failure, 32(6), 1050-1058. https://doi.org/10.1016/j.cardfail.2025.07.013

Vancouver

Berg-Hansen K, Tinggaard AB, Nielsen R, Jensen TH, Gopalasingam N, Larsen AH, et al. Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial. Journal of Cardiac Failure. 2026;32(6):1050-1058. doi:10.1016/j.cardfail.2025.07.013

BibTeX
@article{BergHansen2026,
  author = {Berg-Hansen, Kristoffer and Tinggaard, Andreas Bugge and Nielsen, Roni and Jensen, Thomas Hvid and Gopalasingam, Nigopan and Larsen, Anders Hostrup and Møller, Niels and Böttcher, Morten and Hollingdal, Malene and Poulsen, Mikael Kjær and Antonsen, Lisbeth and Kondo, Toru and Jhund, Pardeep S and Borlaug, Barry A and Mebazaa, Alexandre and Møller, Jacob Eifer and Vraa, Søren and Grand, Johannes and Hove, Jens Dahlgaard and Wolsk, Emil and Schou, Morten and Wiggers, Henrik},
  title = {Should Exogenous Ketone Body Supplementation Be Considered in Patients Hospitalized for Acute Heart Failure? Rationale and Design of the KETO-AHF Trial},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1050--1058},
  doi = {10.1016/j.cardfail.2025.07.013}
}
Kostenlos starten →